Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Joel W. Proksch"'
Publikováno v:
Clinical Ophthalmology, Vol 2010, Iss default, Pp 331-341 (2010)
Gail Torkildsen1, Joel W Proksch2, Aron Shapiro3, Stephanie K Lynch3, Timothy L Comstock21Andover Eye Associates, Andover, Massachusetts, USA; 2Bausch and Lomb, Inc., Rochester, New York, USA; 3Ora, Inc., Andover, Massachusetts, USAPurpose: To evalua
Externí odkaz:
https://doaj.org/article/9c1350542d814eaea9272b7a6ddd5d78
Autor:
Masayuki Yamamoto, Naoki Kashihara, Toshiya Yamamoto, Tamaki Sasaki, Joel W. Proksch, Kengo Kidokoro, W. Christian Wigley, Yuji Sogawa, Minoru Satoh, Colin J. Meyer, Takafumi Suzuki, Hajime Nagasu, Seiji Itano
Publikováno v:
The FASEB Journal
Multiple clinical studies have shown that bardoxolone methyl, a potent activator of nuclear factor erythroid 2-related factor 2 (Nrf2), is effective in increasing glomerular filtration rate in patients with chronic kidney disease. However, whether an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac305a0721ca15787745bc35c3a5153e
http://europepmc.org/articles/PMC6902727
http://europepmc.org/articles/PMC6902727
Autor:
Keith W. Ward, Chun-Yue I. Lee, Sarabjit S Gahir, Mitsumasa Sakamoto, Scott A. Reisman, Joel W. Proksch
Publikováno v:
Drug Design, Development and Therapy. 13:1259-1270
Background Omaveloxolone is a synthetic oleanane triterpenoid that pharmacologically activates Nrf2, a master transcription factor that regulates genes with antioxidative, anti-inflammatory, and mitochondrial bioenergetic properties, and is being eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25c218317af4d50940f3be3d79f04b58
https://doi.org/10.2147/dddt.s193889
https://doi.org/10.2147/dddt.s193889
Autor:
Chris Wigley, Kengo Kidokoro, Yoshihisa Wada, Joel W. Proksch, Megumi Kondo, Naoki Kashihara, Seiji Itano, Atsuyuki Tokuyama, Colin J. Meyer, Tamaki Sasaki
Publikováno v:
Nephrology Dialysis Transplantation. 35
Background and Aims The Keap1/Nrf2 pathway regulates the expression of a series of cytoprotective, anti-inflammatory and antioxidant genes. The Nrf2 activator, bardoxolone methyl (BARD), has consistently increased estimated GFR (eGFR) in clinical stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2391b7d765820ae915814df2c7b0614
https://doi.org/10.1093/ndt/gfaa142.p0089
https://doi.org/10.1093/ndt/gfaa142.p0089
Publikováno v:
Journal of Biochemical and Molecular Toxicology. 34
Omaveloxolone is a potent activator of Nrf2, a master transcriptional regulator of a multitude of cytoprotective functions, including antioxidative, anti-inflammatory, and mitochondrial bioenergetic effects. Some of the most potent known effects of N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c0a9f1824f2f595a1b634a87a57272e
https://doi.org/10.1002/jbt.22526
https://doi.org/10.1002/jbt.22526
Autor:
Colin J. Meyer, Jhanelle E. Gray, Geoffrey T. Gibney, Joseph Markowitz, Mark D. McKee, Scott J. Antonia, Ben C. Creelan, Eric B. Haura, Dmitry I. Gabrilovich, Scott A. Reisman, Tawee Tanvetyanon, Joel W. Proksch, Charles C. Williams, Melanie P. Chin, Jeffrey S. Weber
Publikováno v:
OncoTargets and therapy
Ben C Creelan,1 Dmitry I Gabrilovich,2 Jhanelle E Gray,1 Charles C Williams,1 Tawee Tanvetyanon,1 Eric B Haura,1 Jeffrey S Weber,3 Geoffrey T Gibney,4 Joseph Markowitz,5 Joel W Proksch,6 Scott A Reisman,6 Mark D McKee,7 Melanie P Chin,6 Colin J Meyer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9858385a1bd1677425f6f647b16469a
https://doi.org/10.2147/ott.s136992
https://doi.org/10.2147/ott.s136992
Autor:
Scott A, Reisman, Sarabjit S, Gahir, Chun-Yue I, Lee, Joel W, Proksch, Mitsumasa, Sakamoto, Keith W, Ward
Publikováno v:
Drug Design, Development and Therapy
Background Omaveloxolone is a synthetic oleanane triterpenoid that pharmacologically activates Nrf2, a master transcription factor that regulates genes with antioxidative, anti-inflammatory, and mitochondrial bioenergetic properties, and is being eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1f45cee680b7bd7f75d3159099274880
https://pubmed.ncbi.nlm.nih.gov/31118567
https://pubmed.ncbi.nlm.nih.gov/31118567
Publikováno v:
Archives of Dermatological Research. 306:447-454
RTA 408 is a member of the synthetic oleanane triterpenoid class of compounds known to potently activate the cytoprotective transcription factor Nrf2. Because skin is constantly exposed to external oxidative stress, such as that from ultraviolet radi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c326b6e29eb0a1b4f064db54c1cee138
https://doi.org/10.1007/s00403-013-1433-7
https://doi.org/10.1007/s00403-013-1433-7
Publikováno v:
Drug Metabolism and Disposition. 39:1181-1187
Mapracorat is a selective glucocorticoid receptor agonist in development for the treatment of a variety of ocular diseases. The purpose of this investigation was to evaluate the ocular pharmacokinetics of mapracorat after topical dosing over a range
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b1cff9222828b7a88b3693ac2a3e9b5
https://doi.org/10.1124/dmd.111.039099
https://doi.org/10.1124/dmd.111.039099
Autor:
Joel W. Proksch, Keith W. Ward
Publikováno v:
Journal of Ocular Pharmacology and Therapeutics. 26:449-458
The purpose of this investigation was to evaluate the ocular pharmacokinetic/pharmacodynamic (PK/PD) relationship for besifloxacin, moxifloxacin, and gatifloxacin using rabbit ocular PK data, along with in vitro minimum inhibitory concentration (MIC9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c615c2792120c2cbac79306e55ba04c
https://doi.org/10.1089/jop.2010.0054
https://doi.org/10.1089/jop.2010.0054